(a) (i) What are the different types of epidemiological studies? (ii) What are the possible sources of control in case-control…

Epidemiological Studies

Classification of Epidemiological Studies: Epidemiological studies are classified into observational and experimental designs:

1. Observational Studies:

• Descriptive Studies: Generate hypotheses regarding disease distribution. Examples include case reports, case series, cross-sectional (prevalence) surveys (e.g., National Family Health Survey), and ecological (correlational) studies.
• Analytical Studies: Test formal epidemiological hypotheses. These comprise case-control studies (retrospective, assessing exposure odds) and cohort studies (prospective or retrospective, assessing relative risk and incidence, e.g., Framingham Heart Study).

2. Experimental (Interventional) Studies: Involve active investigator manipulation of exposure. These include Randomized Controlled Trials (RCTs, clinical drug trials), field trials on healthy individuals (e.g., Salk polio vaccine trial), and community trials targeting whole populations (e.g., water fluoridation for dental caries).

Sources of Controls in Case-Control Studies: Controls must represent the source population from which cases arose:

1. Hospital Controls: Non-diseased patients admitted to the same health facility for unrelated conditions (e.g., orthopedic injuries, hernia).
2. General Population Controls: Drawn from electoral registers, census tracts, or vital statistics registers within the same geographical catchment area.
3. Neighborhood Controls: Individuals residing in adjacent households or identical localities to match socioeconomic status.
4. Relatives and Associates: Spouses, siblings, or workplace colleagues, which controls for shared genetic background or occupational exposures.
5. Multiple Control Groups: Utilizing two distinct control sources (e.g., hospital plus community controls) or multiple controls per case (up to 4:1) to minimize selection bias and increase statistical power.

Advantages of Case-Control Studies over Cohort Studies:

• Feasibility in Rare Conditions: Ideal for investigating diseases with low incidence (e.g., rare sarcomas) and long latency periods.
• Resource Efficiency: Inexpensive, rapid to execute, and require substantially smaller sample sizes.
• Multiple Exposures: Allows simultaneous assessment of several putative risk factors for a single disease outcome.
• Operational Viability: Minimizes ethical dilemmas regarding sustained exposure, and eliminates attrition bias (loss to follow-up).

Antenatal Care and Midwifery Services

Definition and Objectives: The World Health Organization (WHO) defines Antenatal Care (ANC) as the systemic medical and psychosocial supervision provided to a pregnant woman from conception until the onset of labor. Its primary objectives are:

• Early screening, detection, and management of high-risk pregnancies (e.g., pre-eclampsia, gestational diabetes mellitus, severe anemia).
• Prevention of adverse maternal and perinatal outcomes via interventions such as Tetanus-Diphtheria (Td) immunization, Iron-Folic Acid (IFA) prophylaxis, and malaria prophylaxis where endemic.
• Health promotion, nutritional counseling, birth preparedness planning, and encouragement of institutional delivery.

Schedule of Antenatal Clinic Visits: Under the National Health Mission (NHM) and WHO basic model, a minimum of four structured antenatal visits is mandated:

• 1st Visit: Within the first trimester (before 12 weeks) for confirmation, baseline screening, and registration.
• 2nd Visit: Between 14 and 26 weeks.
• 3rd Visit: At 28 to 34 weeks.
• 4th Visit: At 36 weeks to term. In ideal obstetrical practice, visits are scheduled monthly up to 28 weeks, fortnightly from 28 to 36 weeks, and weekly thereafter until delivery.

Domiciliary Midwifery Service:

• Advantages: Delivered in the mother's familiar socio-cultural environment, reducing psychological stress; eliminates hospital-related expenditures and transport barriers; lowers the risk of nosocomial infections; and facilitates personalized counseling and family involvement.
• Disadvantages: Inadequate infrastructure to manage sudden, unpredictable intrapartum emergencies (e.g., postpartum hemorrhage, cord prolapse, eclampsia, obstructed labor); suboptimal aseptic conditions; lack of immediate neonatal resuscitation facilities; and dependence on emergency referral and transport systems.

Hematuria and Carcinoma Prostate in a 60-Year-Old Male

Causes of Hematuria:

1. Urological Malignancies: Carcinoma prostate, urothelial carcinoma of the urinary bladder or upper tract, and renal cell carcinoma (RCC).
2. Benign Prostatic Diseases: Benign Prostatic Hyperplasia (BPH) with congested mucosal vascularity.
3. Urolithiasis: Renal, ureteric, or vesical calculi.
4. Urogenital Infections: Acute bacterial prostatitis, cystitis, and genitourinary tuberculosis.
5. Renal Parenchymal/Glomerular Diseases: IgA nephropathy, post-infectious glomerulonephritis, and systemic vasculitides.
6. Trauma and Iatrogenic: Catheter-induced urethral injury, endoscopic interventions, or radiation cystitis.
7. Systemic and Pharmacological: Anticoagulant or antiplatelet therapy, and bleeding diatheses.

Management of Carcinoma Prostate:

1. Staging and Risk Stratification: Workup includes digital rectal examination (DRE), serum Prostate-Specific Antigen (PSA), multiparametric MRI (mpMRI), transrectal ultrasound (TRUS)-guided biopsy (Gleason score / ISUP grade group), and PSMA-PET or bone scan to establish TNM stage and risk category.
2. Localized Disease (T1–T2, N0, M0):

• Low-Risk: Active surveillance involving serial PSA measurements, periodic DRE, and protocolized repeat biopsies.
• Intermediate-to-High Risk: Radical prostatectomy (open, laparoscopic, or robot-assisted) with pelvic lymph node dissection, or definitive External Beam Radiotherapy (EBRT) / Brachytherapy combined with short- or long-term Androgen Deprivation Therapy (ADT).

3. Locally Advanced Disease (T3–T4, N0–N1, M0): High-dose EBRT combined with long-term ADT (2–3 years) using GnRH agonists (e.g., Leuprolide) or antagonists (e.g., Degarelix).
4. Metastatic and Castration-Resistant Disease (M1 / mCRPC):

• Continuous ADT (surgical bilateral orchiectomy or medical castration) paired with next-generation androgen receptor axis-targeted therapies (e.g., Abiraterone acetate with Prednisone, Enzalutamide, Apalutamide) or chemotherapy (Docetaxel).
• For mCRPC: Cabazitaxel, PARP inhibitors (e.g., Olaparib for BRCA-mutated cases), or targeted radioligand therapy with Lutetium-177 PSMA.

5. Monitoring: Serial serum PSA testing every 3 to 6 months to detect biochemical recurrence, alongside bone-health preservation using zoledronic acid or denosumab.